QSAR and docking studies on capsazepine derivatives for immunomodulatory and anti-inflammatory activity

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Shukla, Aparna ^a   Sharma, Pooja ^a   Prakash, Om ^a   Singh, Monika ^a   Kalani, Komal ^a   Khan, Feroz ^a   Bawankule, Dnyaneshwar Umrao ^a   Luqman, Suaib ^a   Srivastava, Santosh Kumar ^a  

^a CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAZEPINE; CAPSAZEPINE 29; CAPSAZEPINE 30; CAPSAZEPINE 33; CAPSAZEPINE 34; CAPSAZEPINE 35; CAPSAZEPINE 36; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CAPSAICIN; CYTOKINE; IMMUNOLOGIC FACTOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CELL VIABILITY; CHEMOPROPHYLAXIS; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; FEMALE; IMMUNOMODULATION; IN VITRO STUDY; MACROPHAGE; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; VALIDATION STUDY; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PROTEIN CONFORMATION; RISK ASSESSMENT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; CAPSAICIN; CELL SURVIVAL; CYTOKINES; DRUG EVALUATION, PRECLINICAL; FEMALE; IMMUNOLOGIC FACTORS; MACROPHAGES; MICE; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RISK ASSESSMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903879021     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100797     Document Type: Article

References (31)

1. Jansco G, Kir Aly E, Jansco-Gabor A (1977) Pharmacologically induced selective degeneration of chemosensitive primary sensory neurons. Nature 270: 741.
2. Szallasi A, Blumberg PM (1999) Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Re V 51: 1592212.
3. Caterina MJ, Julius D (2001) The vanilloid receptor: a molecular gateway to the pain pathway. Annu Re V Neurosci 24: 4872517.
4. Appendino G, Munoz E, Bernd L Fiebich (2003) TRPV1 (vanilloid receptor,capsaicin receptor) agonists and antagonists. Expert Opin Ther Patents 3: 182521837.
5. Macho A, Calzado MA, Mun,oz-Blanco J, et al. (1999) Selective induction of apoptosis by capsaicin in transformed cells: the role of reactive oxygen species and calcium. Cell Death Differ 6: 1552165.
6. Uchida M, Yano S, Watanabe K (1991) The role of capsaicin sensitive afferent nerves in protective effect of capsaicin against absolute ethanol-induced gastric lesions in rats. Jpn J Pharmacol 55: 2792282.
7. Cichewicz RH, Thorpe PA (1996) The antimicrobial properties of chile peppers (Capsicum species) and their uses in Mayan medicine. J Ethnopharmacol 52: 61270.
8. Franco-Cereceda A, Lundberg JM (1988) Actions of calcitonin generelated peptide and tachykinins in relation to the contractile effects of capsaicin in the guinea-pig and rat heart in vitro. Naunyn Schmiedebergs Arch Pharmacol 337: 6492655.
9. Srinivasan MR, Satyanarayana MN (1989) Effect of capsaicin on lipoprotein lipase in rats fed high fat diet. Indian J Exp Biol 27: 9102912.
10. Walpole CS, Bevan S, Bovermann G, Boelsterli JJ, Breckenridge R, et al. (1994) The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin. J Med Chem 37: 194221954.
11. Chen CW, Lee ST, Wu WT, Fu WM, Ho FM, et al. (2003) Signal transduction for inhibition of inducible nitric oxide synthase and cyclooxygenase-2 induction by capsaicin and related analogues in macrophages. Br J Pharmacology 140: 107721087.
12. Oh GS, Pae HO, Seo WG, Kim NY, Pyun KH, et al. (2001) Capsazepine, a vanilloid receptor antagonist, inhibits the expression of inducible nitric oxide synthase gene in lipopolysaccharide-stimulated RAW 264.7 macro-phages through the inactivation of nuclear transcription factor-kappa. B Int Immunopharmacol 1: 7772784.
13. Luqman S, Meena A, Marler LE, Kondratyuk TP, Pezzuto JM (2011) Suppression of tumor necrosis factor-a-induced nuclear factor B activation and aromatase activity by capsaicin and its analog capsazepine. J Med Food 14: 1344251.
14. Melisi D, Chiao PJ (2007) NFkB as a target for cancer therapy. Expert Opin Ther Targets 11: 1332144.
15. Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 139721421.
16. Chen F, Castranova V, Shi X (2001) New insights into the role of nuclear factor jB in cell growth regulation. Am J Pathol 159: 3872397.
17. Thanos D, Maniatis T (1995) NFkB: a lesson in family values. Cell 80: 5292532.
18. Luqman S, Pezzuto JM (2010) NFkB: a promising target for natural products in cancer chemoprevention. Phytother Res 24: 9492963.
19. Fujita M, Hirayama T, Ikeda N (2002) Design, synthesis and bioactivities of novel diarylthiophenes: inhibitors of tumor necrosis factor-alpha (TNF-alpha) production, Bioorg Med Chem Lett 12: 160721611.
20. Fujita M, Seki T, Ikeda N (2002) Synthesis and bioactivities of novel bicyclic thiophenes and 4,5,6,7-tetrahydrothieno[2,3-c]pyridines as inhibitors of tumor necrosis factor-alpha (TNF-alpha) production, Bioorg Med Chem Lett 12(15) 189721900.
21. Cheng JF, Ishikawa A, Ono Y, Arrhenius T, Nadzan A (2003) Novel Chromene Derivatives as TNF- Inhibitors, Bioorg Med Chem Lett 13(21):3647250.
22. Cheng JF, Chen M, Wallace D, Tith S, Arrhenius T, et al. (2004) Bioorg Med Chem Lett 14(10):2411-5.
23. Fujita M1, Hirayama T, Ikeda N (2002) Design, synthesis and bioactivities of novel diarylthiophenes: inhibitors of tumor necrosis factor-alpha (TNF-alpha) production, Bioorg Med Chem 10: 3113-3122.
24. Chao Q, Deng L, Shih H, Leoni LM, Genini D, et al. (1999) Substituted isoquinolines and quinazolines as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha, J Med Chem 42(19):3860-3873.
25. Bawankule DU, Chattopadhyay SK, Pal A, Saxena K, Yadav S, et al. (2008) Modulation of inflammatory mediators by coumarinolignoids from Cleome viscose in female Swiss albino mice. Inflammopharmacology 16: 272-277.
26. Brown E, Yedjou CG Tchounwou PB (2008) Cytotoxicity and oxidative stress inhuman liver carcinoma cells exposed to arsenic trioxide (HepG2), Met Ions Biol Med 10, 583-587.
27. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19: 1639-1662.
28. Lipinski CA, Lombardo F, Dominy B, Feeney P (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
29. Meena A, Yadav DK, Srivastava A, Khan F, Chanda D, et al. (2011) In silico exploration of anti-inflammatory activity of natural coumarinolignoids. Chem Biol Drug Des 78: 567-79.
30. Yadav DK, Meena A, Srivastava A, Chanda D, Khan F, et al. (2010) Development of QSAR model for immunomodulatory activity of natural coumarinolignoids. Drug Des Devel Ther 4: 173-86.
31. Alam S, Khan F (2014) QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase II, Drug Des Devel Ther 8: 183-195.